Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26077042 | 1.00 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL27407476 | 0.82 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL21503867 | 0.82 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL22788858 | 0.82 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL23743699 | 0.82 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL22695761 | 0.82 | ALDH1A1 (0.36) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL3338670 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL29697722 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL17305531 | 0.82 | ALDH1A1 (0.55) | ALDH1A1LMNAMAPTPTGS2TDP1 | |
| SCHEMBL22790532 | 0.81 | ECE1 (0.33) | ALDH1A1LMNAMAPTPTGS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190951-A1 | CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS | SYNAFFIX B.V. (NL) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190951-A1 | CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS | FCGR3B, FCGR1A, FCGR2A | ALDH1A1 3456/4885LMNA 4334/4885MAPT 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.